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gIn acute coronary syndrome (ACS) patients under-
going percutaneous coronary intervention (PCI),
identification of culprit lesions and other potentially
significant stenoses most often utilizes coronary
angiography. The PROSPECT (Providing Re-
gional Observations to Study Predictors of Events
in the Coronary Tree) study, used multimodality
coronary artery imaging (greyscale and radiofre-
quency intravascular ultrasound, in addition to
angiography) to describe the natural history of
coronary atherosclerosis after PCI for ACS.
PROSPECT was a landmark study that under-
scored the systemic nature of atherosclerosis, dem-
onstrating that initially mild, nonculprit lesions
(NCLs) accounted for about half of subsequent
events in patients followed for 3 years. The charac-
teristics associated with future events included
See pages S42, S53, and S62
plaque burden 70%, minimum lumen area 4
mm2, and presence of thin-cap fibroatheroma in
lesions that were assessed angiographically to be
50% stenosed at the time of index presentation;
adverse events were increasingly frequent if 1, 2, or
all 3 of these features were present. The effects on
outcome of the extent of CAD, the influence of
NCLs on future MACE events, and the influence
of plaque composition in the important subgroups
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contents of this paper to disclose.f diabetic patients, women, and those patients with
hronic kidney disease (CKD) from PROSPECT
re addressed in this issue of iJACC. Such subanaly-
es may give important insight into potential mech-
nisms for what we have previously observed in
arge outcomes studies.
In ACS, diabetes has long been associated with
ncreased cardiovascular risk of events compared to
ondiabetic patients (1–3). On the other hand,
here is less understanding of the risk of metabolic
yndrome or impaired glucose tolerance. Marso et
l. (4) demonstrate a strong gradient of cardiovas-
ular (CV) risk from diabetes to metabolic syn-
rome to normoglycemia for major adverse cardiac
vents (MACE) rates (29.4% vs. 21.3% vs. 17.4%).
most intriguing observation in their PROS-
ECT substudy was that there was a disproportion-
te number of MACE in the diabetic group attrib-
table to NCLs (about two-thirds, 18.7% of
9.4%), compared with the approximately 50%
ontribution of NCLs to 3-year event rate in the
ain PROSPECT trial and the other 2 subgroups
f women and CKD. This is complementary to the
ndings of Cutlip et al. (5), who described that for
iabetic patients, nontarget lesions were associated
ith the majority of clinical events after the first
ear post-PCI. The finding that long lesions and
esions with a greater proportion of necrotic core
nd calcium were associated with increased risk also
nderscores the incremental value of multimodality
oronary imaging in assessing future risk. Further
tudy is required to determine the relationship
etween plaque composition, MACE, and degree
f control of cardiovascular risk factors (6). Are the
iabetic patients that are not meeting risk factor
oals, or with more advanced stage/longer duration
f diabetes, more likely to have NCLs with high-
J A C C : C A R D I O V A S C U L A R I M A G I N G , V O L . 5 , N O . 3 , S U P P L S , 2 0 1 2
M A R C H 2 0 1 2 : S 7 3 – 5
Farkouh and Mathew
Editorial Comment
S74risk features and therefore more likely to experience
MACE?
In an accompanying paper, Lansky et al. (7)
sought to evaluate the impact of sex on character-
istics of coronary plaque in the PROSPECT study.
Interestingly, women, as expected, were older and
had more comorbid disease when compared with
men, but had fewer NCLs overall. As expected
from other studies, there were no differences in
MACE rates between men and women although
there were gender differences for which plaque
subtypes predicted future risk (thin-cap fibroathe-
roma for women and plaque burden for men).
Plaque rupture occurred less commonly in women,
and the investigators hypothesize that this may
explain why women present more often with typical
or atypical chest pain syndromes rather than frank
ACS. Although the pathophysiology and plaque
composition of CAD leading to ACS may be quite
different between the sexes, the differences appear
to be off-setting with respect to clinical outcomes,
and appear to validate the current practice whereby
men and women are treated in a similar fashion (8).
Baber et al. (9) reported on the influence of CKD
on plaque composition morphology and outcomes
in the PROSPECT study. As in patients with
diabetes, patients with CKD are at increased risk
for MACE at the time of an ACS (10). Even more
importantly, patients with CKD may have in-
creased risk even if they are treated for their
traditional risk factors. Similar to the graded CV
risk of dysglycemia from metabolic syndrome to
diabetes, there is also a continuum that has been
identified for CKD. In the current analysis from the
PROSPECT investigators, CKD was defined by an
estimated glomerular filtration rate 60 ml/min,
although the cohort on average had mild CKD
(stage I) with a mean glomerular filtration rate of 51
ml/min. Those with CKD were characterized by a
greater degree of diabetes and hypertension, were
more likely to present with a non–ST-segment
elevation MI, and experienced a higher rate of
3-year MACE events. Patients with CKD were
more often noted to have lesions with MLA 4
mm2, greater plaque burden, a trend toward longer
lesion length, and had a higher proportion of
necrotic core when compared with those without
CKD. The difference in subsequent events between
those with and without CKD was primarily attrib-
utable to culprit lesions; unlike diabetes, CKD was
not associated with disproportionate number of
MACE attributable to NCLs. Could this explain
the reduced benefit of optimal medical therapy inCKD patients compared with those with diabetes,
or is it merely an inability to draw firm conclusions
due to the small sample size and inclusion of relatively
mild CRF patients. However, the findings do raise the
question as to whether there is a different biology of
atherosclerosis for CKD compared with diabetes,
which merits further understanding (11).
PROSPECT and these subanalyses highlight 3
major points that merit our attention. First, the fact
that NCLs account for 50% and more of the events
in the ensuing 3 years after angiographically tar-
geted lesion revascularization for ACS underscores
the nonfocal nature of atherosclerosis. These lesions
to date are generally addressed with medical ther-
apy, and the findings remind us of the importance
of optimizing medical therapy and plaque stabiliza-
tion after ACS PCI. Second, complementary cor-
onary imaging aids in identifying NCLs that are
more likely to lead to adverse events. Third, impor-
tant baseline characteristics may dictate how we
approach NCLs in the future. In diabetic patients,
NCLs account for a disproportionate number of
events, and therefore they may be of greater impor-
tance. This may mean that patients need to be
treated more aggressively from a medical standpoint
for systemic risk factor modification and stabiliza-
tion of these lesions, or potentially have NCLs with
multiple plaque characteristics that portend risk
treated by novel interventional strategies that are yet
to be tested. On the other hand, patients with CKD
have greater MACE, but these events are not due
primarily to differences in nonculprit lesions, but
rather to differences in culprit lesions, and yet the
beneficial effects of optimal lipid control have
also been demonstrated in this population (12).
Whether the discordant findings regarding the
influence of NCLs on subsequent events in dia-
betic versus CKD patients is explained by biolog-
ical differences in atherosclerosis between these 2
often overlapping subgroups merits further study.
The insights from the PROSPECT study and
substudies are intriguing to clinical cardiologists.
The identification and characterization of NCLs
that will account for future CV events appears to be
an exciting area of ongoing investigation, and
should utilize a patient-specific, plaque-specific ap-
proach. For the clinician, it reminds of the impor-
tance of systemic medical management with phar-
macotherapy in the long-term treatment of patients
after ACS. What is clear is that many of our
patients are prescribed medications directed at
treating risk factors, but only a fraction of patients
reach targets for low-density lipoprotein choles-
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and blood pressure. One might ask how the results
from PROSPECT would look if patients were
under optimal medical control.
The objectives for the future should consider:
1) a patient-level scoring system to define those at
high risk for NCL-associated MACE based on
PROSPECT-driven lesion characterization at the
time of PCI for ACS, which should include a measure
of CV risk factors; 2) interventional trials to test thecoronary stent trials. Circulation 2004;
110:1226–30.
nary syndromes. J
Img 2012;5 Supplculprit lesions; and 3) utilizing emerging noninvasive
strategies such magnetic resonance, computed tomog-
raphy, and positron emission tomography to charac-
terize plaque at the extracoronary and coronary level.
These important studies introduce the prospect for
major advances in the years to come.
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